The results demonstrated that the distribution of sgRNAs in the two groups was relatively uniform (Figure S3A), and the number of genes in the PD1-treated group and the control group was linearly symmetrical, indicating that most genes did not affect the efficacy of anti-PD1 immunotherapy and only a few genes might be related to the outcome of anti-tumor immunity (Figure S3B). Here, PDCD1 is linked to neoplasm.